CIITA

Across TCGA pan-cancer cohorts, CIITA Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CIITA data layer compared with 21 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CIITA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CIITA expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

KIRP, OV, and BLCA are the cancer types where CIITA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.132	0.904	<.001	36	view →
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
BLCA	DFS	Median	III,IV	1.000	0.425	.008	23	view →
LUAD	OS	Median	All	0.338	0.834	.004	21	view →
STAD	DFS	Median	All	0.909	0.384	.018	14	view →
SKCM	DFS	Median	All	0.880	0.724	.005	14	view →
READ	DFS	Median	All	0.182	0.798	.010	9	view →
LUSC	OS	Median	All	0.222	0.729	.005	9	view →
DLBC	OS	Median	All	0.570	0.939	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CIITA–KIRP (OS)

Open the KIRP breakdown →